AstraZeneca is celebrating two new approvals for cancer therapies Imfinzi and Enhertu in the EU as it faces the threat of ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...

Dividend King stocks can succumb to management complacency or over conservative policies that can dull a competitive edge, ...

Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64B after a jury found it liable in a ...